US4568343A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Skin permeation enhancer compositions
Assignee: Alza Corp
•
Filing: 1984-10-09
•
Granted: 1986-02-04
•
Expires: 2004-10-09
Abstract
Abstract A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with polyethylene glycol monolaurate. Preferred embodiments of transdermal therapeutic systems for delivering drug and polyethylene glycol monolaurate employ matrix containing drug at a concentration above saturation.
Inventors
- 👤 Harold M. Leeper
- 👤 Diane Nedberge
- 👤 Lina T. Taskovich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/0012; A61K9/0014; A61K9/7084
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
42 words
A composition of matter for application to a body surface or membrane to deliver a biologically active agent by permeation through a body surface or membrane comprising, in combination; a biologically active agent and a permeation enhancing amount of polyethylene glycol monolaurate.
Claim 2
Dependent Claim
42 words
A composition of matter for application to a body surface or membrane to deliver a biologically active agent by permeation through a body surface or membrane comprising, in combination; a biologically active agent and a permeation enhancing amount of polyethylene glycol monolaurate.
Claim 3
Dependent Claim
18 words
The composition of claim 1 when said agent and polyethylene glycol monolaurate are dispersed within a carrier therefor.
Claim 4
Dependent Claim
22 words
The composition of claim 2 wherein said agent is present in an amount in excess of its saturation concentration in the carrier.
Claim 5
Dependent Claim
26 words
The composition of claim 1 wherein the polyethylene glycol component of said polyethylene glycol monolaurate has an average molecular weight in the range of about 200-400.
Claim 6
Dependent Claim
17 words
The composition of claims 1, 3, or 4 wherein said body surface or membrane is intact skin.
Claim 7
Dependent Claim
47 words
A transdermal therapeutic system comprising the composition of claims 1, 2, 3 or 4 in combination with: (a) an occlusive backing behind the skin distal surface of said composition, and (b) means for maintaining said composition in agent and polyethylene glycol monolaurate transferring relationship to intact skin.
Claim 8
Independent Claim
46 words
A method for enhancing the flux of a biologically active agent through a body surface or membrane which comprises placing a source of said agent in agent transmitting relationship to said surface or membrane in the presence of a permeation enhancing amount of polyethylene glycol monolaurate.
Claim 9
Independent Claim
46 words
A method for enhancing the flux of a biologically active agent through a body surface or membrane which comprises placing a source of said agent in agent transmitting relationship to said surface or membrane in the presence of a permeation enhancing amount of polyethylene glycol monolaurate.
Claim 10
Dependent Claim
22 words
The method of claim 7 wherein the source of said agent contains agent in excess of its saturation concentration in said source.
Claim 11
Dependent Claim
16 words
The method of claim 7 or 8 wherein said body surface or membrane is intact skin.
Claim 12
Dependent Claim
73 words
In a method for administering a biologically active agent by permeation through an intact body surface which comprises: (a) placing a source of said agent and a permeation enhancer therefor in agent and permeation enhancer transmitting relationship to said body surface, and (b) maintaining said source in contact with said body surface for a period of time sufficient to produce a beneficial effect; the improvement wherein said permeation enhancer is polyethylene glycol monolaurate.
Claim 13
Dependent Claim
73 words
In a method for administering a biologically active agent by permeation through an intact body surface which comprises: (a) placing a source of said agent and a permeation enhancer therefor in agent and permeation enhancer transmitting relationship to said body surface, and (b) maintaining said source in contact with said body surface for a period of time sufficient to produce a beneficial effect; the improvement wherein said permeation enhancer is polyethylene glycol monolaurate.
Claim 14
Dependent Claim
12 words
The method of claim 10 wherein said body surface is the skin.
Claim 15
Dependent Claim
22 words
The method of claim 11 wherein the polyethylene glycol component of said polyethylene glycol has an average molecular weight of about 200-400.
Claim 16
Dependent Claim
54 words
In a transdermal therapeutic system comprising: (a) a source of a transdermally deliverable biologically active agent, (b) a source of a skin permeation enhancer for said agent and (c) means for maintaining said system in agent and permeation enhancer transferring relationship to intact skin; the improvement wherein said permeation enhancer is polyethylene glycol monolaurate.
Claim 17
Dependent Claim
54 words
In a transdermal therapeutic system comprising: (a) a source of a transdermally deliverable biologically active agent, (b) a source of a skin permeation enhancer for said agent and (c) means for maintaining said system in agent and permeation enhancer transferring relationship to intact skin; the improvement wherein said permeation enhancer is polyethylene glycol monolaurate.
Claim 18
Dependent Claim
18 words
The system of claim 13 wherein said agent is present in said source at a concentration above saturation.
Claim 19
Dependent Claim
12 words
The system of claim 12 wherein said PEGML is PEG 200-400 ML.
Claim 20
Dependent Claim
45 words
The system of claim 13 wherein said agent is present at a concentration sufficient to maintain the concentration above saturation for an extended period of time and said PEGML is present at a concentration sufficient to provide permeation enhancement throughout said extended period of time.
References Cited (Backward Citations)
GB1001949A
Cited
US3527864A
Cited
US3472931A
Cited
US3598122B1
Cited
US3598122A
Cited
US3598123A
Cited
US3903256A
Cited
US3896238A
Cited
US3952099A
Cited
US4046886A
Cited
US4144317A
Cited
US4405616A
Cited
US4130643A
Cited
US4130667A
Cited
US4335115A
Cited
US4201211A
Cited
US4299826A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4460372A
Cited
US4343798A
Cited
US4435180A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-02-03 | 1989-08-05 | 1990-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-02-03 | 1993-08-05 | 1994-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-02-03 | 1997-08-05 | 1998-02-04 | $7700.00 | Window Closed / Lapsed |